Core Insights - Artisan Small Cap Fund aims to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - The Fund experienced strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, despite elevated volatility and shifting market sentiment [1] - For the full year 2025, the Fund generated strong results but underperformed compared to both indexes [1] - The market leadership in Q4 2025 shifted back to companies with durable profit cycles, and the firm plans to continue focusing on identifying profit cycles in franchise companies at reasonable valuations moving into 2026 [1] Company Focus: Penumbra, Inc. - Penumbra, Inc. is highlighted as a key stock in the Fund's portfolio, specializing in medical devices for peripheral thrombectomy products [2] - As of March 16, 2026, Penumbra's stock closed at $336.21, with a one-month return of -1.41% and a twelve-month increase of 22.13% [2] - Penumbra has a market capitalization of $13.194 billion [2] - The Fund added to its position in Penumbra during Q4 2025 due to growing adoption of its core products, strong clinical outcomes, and a favorable safety profile [3] - The company is benefiting from competitive disruption and a more specialized sales force, with upcoming regulatory approvals for next-generation devices expected to further accelerate its profit cycle [3]

Core Insights - Penumbra, Inc. reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.18, exceeding the Zacks Consensus Estimate by 5.36% and showing a significant increase from 85 cents in the same quarter last year [1] - The company’s revenues for the quarter reached $385.4 million, reflecting a year-over-year increase of 22.1% and surpassing the Zacks Consensus Estimate by 6.74% [2] - Penumbra announced a definitive agreement to be acquired by Boston Scientific, valuing the company at approximately $14.5 billion, leading to the cessation of financial guidance for 2026 [9] Revenue Performance - Total revenues for the fourth quarter were $385.4 million, up 22.1% year over year, with a full-year revenue of $1.40 billion, marking a 17.5% increase from the previous year [2] - U.S. revenues accounted for $299.1 million (77.6% of total revenues), increasing by 20.6% year over year, while international revenues rose by 27.7% to $86.3 million [3] - Thrombectomy product sales reached $254.7 million, up 15.7%, and Embolization and Access products totaled $130.7 million, up 22.1% [4] Margin Analysis - Gross profit for the quarter improved by 24.4% to $262.1 million, with a gross margin expansion of 123 basis points to 68% despite a 17.6% increase in the cost of revenues [5] - Selling, general and administrative expenses rose by 22.4% to $181.1 million, while research and development expenses increased by 8.9% to $21.8 million [6] - Adjusted operating profit was $59.2 million, up from $42.8 million in the previous year, with an adjusted operating margin expansion of 181 basis points to 13.4% [6] Financial Position - At the end of the fourth quarter, Penumbra had cash and marketable investments totaling $544.8 million, an increase from $340.1 million at the end of 2024 [7] Clinical Developments - The company announced results from the STORM-PE trial, demonstrating that mechanical thrombectomy with anticoagulation significantly reduced right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism [11]

Core Insights - Penumbra, Inc. is a leading company in the medical instruments sector, particularly recognized for its thrombectomy products, and has demonstrated strong financial performance in its recent earnings report [1] Financial Performance - The company reported earnings of $1.18 per share, exceeding the Zacks Consensus Estimate of $1.12, resulting in a 5.36% earnings surprise and a significant increase from $0.97 per share reported a year ago [2][6] - Revenues for the quarter ending December 2025 reached $385.39 million, surpassing the Zacks Consensus Estimate by 6.74% and reflecting a 22.1% increase compared to $315.52 million in the same period last year [3][6] Revenue Breakdown - The United States contributed 77.6% of Penumbra's total revenue, with international markets accounting for 22.4%. U.S. revenue increased by 20.6%, while international revenue grew by 27.7% [4] - Sales of global thrombectomy products amounted to $254.7 million, primarily driven by strong sales in the U.S. market [4] Stock Performance - The current trading price of PEN is $341.11, showing a 0.72% increase, with a market capitalization of approximately $13.38 billion. The stock has fluctuated between $338.82 and $341.12 today [5] - Over the past year, PEN has reached a high of $362.41 and a low of $221.26, indicating a dynamic market presence [5] Analyst Outlook - UBS has set a price target of $374 for PEN, suggesting a potential increase of about 9.92% from its current trading price of $340.24, reflecting strong investor confidence [1][6]

Core Insights - Penumbra reported revenue of $385.39 million for the quarter ended December 2025, reflecting a year-over-year increase of 22.1% and exceeding the Zacks Consensus Estimate by 6.74% [1] - The company's EPS for the quarter was $1.18, up from $0.97 in the same quarter last year, surpassing the consensus estimate of $1.12 by 5.36% [1] Revenue Performance - U.S. revenue reached $299.05 million, exceeding the average estimate of $289.07 million, with a year-over-year growth of 20.6% [4] - International revenue totaled $86.33 million, surpassing the average estimate of $73.9 million, marking a year-over-year increase of 27.7% [4] - Revenue from Embolization and Access in the U.S. was $95.99 million, exceeding the average estimate of $80.72 million [4] - Revenue from Thrombectomy in the U.S. was $203.07 million, slightly below the average estimate of $208.34 million [4] - International revenue from Embolization and Access was $34.7 million, compared to the estimated $31.06 million [4] - International revenue from Thrombectomy was $51.63 million, exceeding the average estimate of $42.84 million [4] - Overall revenue from Embolization and Access was $130.69 million, surpassing the average estimate of $111.78 million, with a year-over-year change of 37% [4] - Overall revenue from Thrombectomy was $254.7 million, slightly above the average estimate of $251.19 million, reflecting a year-over-year increase of 15.7% [4] Stock Performance - Penumbra's shares have returned -5.5% over the past month, compared to a -0.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - Penumbra (PEN) reported quarterly earnings of $1.18 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and showing an increase from $0.97 per share a year ago, representing an earnings surprise of +5.36% [1] Financial Performance - The company achieved revenues of $385.39 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 6.74%, and up from $315.52 million year-over-year [2] - Over the last four quarters, Penumbra has consistently exceeded consensus EPS estimates and revenue estimates [2] Stock Performance - Penumbra shares have increased approximately 9.2% since the beginning of the year, compared to a 0.7% gain in the S&P 500 [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, with current consensus EPS estimates at $1.12 for the upcoming quarter and $5.06 for the current fiscal year [7] - The Zacks Rank for Penumbra is currently 4 (Sell), indicating expectations of underperformance in the near future [6] Industry Context - The Medical - Instruments industry, to which Penumbra belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8]

Financial Performance - Revenue for the year ended December 31, 2025, was $1,403.7 million, representing a 17.5% increase from $1,194.6 million in 2024 and a 32.4% increase from $1,058.5 million in 2023[25] - Income from operations for the year ended December 31, 2025, was $189.2 million, compared to $9.3 million in 2024 and $73.6 million in 2023[25] - In 2025, direct sales accounted for approximately 90% of the company's revenue, with the remainder generated by independent distributors and licensing arrangements in China[69] - The company's gross margin for the year ended December 31, 2025, was positively impacted by a favorable product mix and productivity improvements, with price changes having a minimal effect[377] Product Development and Innovation - The thrombectomy product category generated revenue of $947.9 million, $815.5 million, and $677.3 million for the years ended December 31, 2025, 2024, and 2023, respectively[29] - The embolization and access product categories generated revenue of $455.7 million, $379.1 million, and $381.2 million for the years ended December 31, 2025, 2024, and 2023, respectively[29] - The company launched Lightning Flash in 2023, an advanced mechanical thrombectomy system, and plans to introduce Lightning Flash 2.0 in 2024 and Lightning Flash 3.0 in 2025, enhancing efficiency and sensitivity to thrombus[39] - The Ruby Embolization Platform, launched in 2025, is designed for efficient embolization in large vessels and high-flow situations[47] - The Penumbra Coil 400 offers higher packing density with fewer coils compared to competitors, targeting small to large aneurysms[51] - The Neuron family of guide catheters improves access and trackability in the neurovasculature, enhancing procedural efficiency[56] - The MIDWAY intermediate catheter family, launched in 2024, is designed to deliver various embolization devices through guide catheters[59] - The Penumbra System includes aspiration-based products for revascularization in acute ischemic stroke, improving clinical outcomes and reducing procedure times[40] - The Artemis Neuro Evacuation Device offers a minimally invasive approach for hematoma evacuation, enhancing surgical outcomes[60] Strategic Decisions and Business Operations - The company made a strategic decision to exit its immersive healthcare business, incurring $115.3 million in impairment and other charges in 2024[26] - The company has invested heavily in product development and commercial expansion since its founding in 2004, establishing a strong foundation for its global organization[22] - The company entered into a Merger Agreement with Boston Scientific Corporation, reflecting an enterprise value of approximately $14.5 billion, with each share valued at $374[27] - The Merger is expected to close by the end of 2026, subject to customary closing conditions, including stockholder and regulatory approvals[27] Market and Competition - The company faces intense competition in the medical device industry, competing with large companies like Boston Scientific and Medtronic[77] - Approximately 2.15 million incidences of clot in the vasculature occur each year in the United States, with the majority not receiving mechanical thrombectomy intervention[31] - Approximately 8.5 million acute myocardial infarctions (AMIs) occur annually, with 500,000 occurring in the U.S., leading to about 350,000 deaths each year[35] - The company estimates that 60% of U.S. AMIs, approximately 300,000 patients, are eligible for mechanical thrombectomy[35] Regulatory Compliance - The company is subject to extensive regulation by the FDA, requiring premarket clearance or approval for its medical devices[83] - FDA has 180 days to review a PMA application, but the process can take several years[90] - Upon completion of the PMA review, FDA may approve the application, issue an approvable letter, or deny it, with a response period of 180 days for the applicant[91] - Clinical trials for significant risk devices require an IDE application, which must be approved by FDA and relevant IRBs before trials can begin[92] - Manufacturers must register with clinicaltrials.gov, providing public information about clinical trials, including device details and study sites[94] - Changes to an approved PMA device require submission and FDA approval of a new PMA application or supplement[96] - FDA regulations mandate the registration of manufacturing facilities and compliance with the Quality Management System Regulation (QMSR)[97] - Manufacturers must report to FDA if their device may have caused or contributed to a death or serious injury, or if a malfunction could lead to such outcomes[99] - Newly discovered safety data may necessitate changes to product labeling and risk management measures[100] - The company is subject to periodic FDA inspections, which may result in corrective actions if deficiencies are identified[102] - The company must comply with various federal and state healthcare laws, including the Anti-Kickback Statute, which prohibits certain remuneration practices[108] Workforce and Facilities - As of December 31, 2025, the company had approximately 4,700 employees worldwide, with over 45% being female and more than 70% from a minority background[117] - The company maintains approximately 610,000 square feet of office, research and development, manufacturing, and administrative facilities in Alameda, California, with leases expiring at various times in 2036[119] - The company entered into agreements to acquire property in Costa Rica for a new manufacturing facility and warehouse for medical devices, with a lease for approximately 46,000 square feet commencing in 2026[121] - The company has a dedicated Employee Health and Safety team to prevent workplace risks, supported by a strategic plan regularly reviewed[124] - The company provides competitive wages and benefits, aiming for internal pay equity and promoting from within to foster employee growth[118] - The company has never experienced a work stoppage and believes its employee relations are good[117] Risk Management - The company utilizes long-term supply contracts with some suppliers to manage risks associated with raw material availability and price increases[65] - The company does not currently hedge its exposure to foreign currency exchange rate fluctuations, although it operates in multiple currencies, primarily billing in euros[376] - A hypothetical 100 basis point change in interest rates would not materially impact the value of the company's cash and cash equivalents or marketable investments[375]

Core Insights - Penumbra, Inc. reported strong financial results for the fourth quarter and full year 2025, highlighting significant revenue growth and improved profitability metrics [1] Financial Highlights - Full year 2025 net income reached $177.7 million, with an adjusted EBITDA of $266.8 million, resulting in a net income margin of 12.7% and an adjusted EBITDA margin of 19.0% [1] - Fourth quarter 2025 net income was $47.3 million, with adjusted EBITDA of $79.1 million, yielding a net income margin of 12.3% and an adjusted EBITDA margin of 20.5% [1] - Total revenue for the full year 2025 was $1,403.7 million, marking a 17.5% increase compared to 2024, or 16.9% in constant currency [1] - Fourth quarter revenue was $385.4 million, a 22.1% increase from the same quarter in 2024, or 20.9% in constant currency [1] Revenue Breakdown - U.S. thrombectomy revenue for the full year 2025 was $771.5 million, up 19.3% from 2024 [1] - Fourth quarter U.S. thrombectomy revenue was $203.1 million, reflecting a 12.4% increase year-over-year [1] - International revenue for the full year 2025 increased by 6.6%, or 4.2% in constant currency, while fourth quarter international revenue grew by 27.7%, or 21.9% in constant currency [1] Product Performance - Global thrombectomy product sales in the fourth quarter reached $254.7 million, a 15.7% increase year-over-year [1] - Sales of global embolization and access products grew to $130.7 million in the fourth quarter, a 37.0% increase compared to the same period in 2024 [1] Operating Metrics - Gross profit for the fourth quarter of 2025 was $262.1 million, representing 68.0% of total revenue, compared to 66.8% in the fourth quarter of 2024 [1] - Total operating expenses for the fourth quarter were $202.9 million, or 52.6% of total revenue, down from 53.2% in the same quarter of 2024 [1] - Income from operations for the fourth quarter was $59.2 million, compared to $42.8 million in the fourth quarter of 2024 [1] Future Outlook - The company will not provide financial guidance for the full year 2026 due to the proposed acquisition by Boston Scientific Corporation [1]

Core Insights - Coloplast A/S Sponsored ADR (CLPBY) is currently rated as a Buy (2) according to the Zacks Rank, while Penumbra (PEN) is rated as a Sell (4), indicating a more favorable earnings outlook for CLPBY [3] - Value investors utilize various traditional metrics to identify undervalued companies, including P/E ratio, P/S ratio, earnings yield, and cash flow per share [4] Valuation Metrics - CLPBY has a forward P/E ratio of 19.03, significantly lower than PEN's forward P/E of 67.01, suggesting that CLPBY may be undervalued [5] - The PEG ratio for CLPBY is 0.75, while PEN's PEG ratio is 2.09, indicating that CLPBY has a better balance between its price and expected earnings growth [5] - CLPBY's P/B ratio stands at 7.91 compared to PEN's 9.78, further supporting the argument that CLPBY is more attractively valued [6] Conclusion - Given the stronger estimate revision activity and more favorable valuation metrics, CLPBY is positioned as the superior investment option for value investors at this time [7]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid capacity and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports and benefiting from the onshoring trend driven by tariffs [5][6] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms burdened by debt [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without the associated premium [9] Market Trends - The article discusses the broader trends of AI, energy, tariffs, and onshoring, indicating that this company is strategically aligned with these developments [6][14] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the potential for growth in AI investments [12] Future Outlook - The company is positioned at the heart of America's next-generation power strategy, particularly in nuclear energy, which is seen as a clean and reliable power source for the future [7][14] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19]

Core Thesis - Penumbra, Inc. (PEN) is viewed positively due to its leading position in the thrombectomy market and strong operational fundamentals, despite recent stock price fluctuations driven by sector rotation [1][2][3][4]. Company Overview - Penumbra, Inc. specializes in thrombectomy and holds a near-monopoly position in the market, supported by proprietary catheter systems and software that enhance procedural precision [2]. - The company has a strong balance sheet with no debt, robust free cash flow, and improving margins, indicating operational excellence [4]. Stock Performance - PEN's stock has historically shown a predictable trading pattern, rallying into the low $300s and then selling off into the low $200s over the past five years [3]. - The recent stock pullback is attributed to broader sector rotation rather than any operational issues within PEN, positioning it attractively for future investment [3][4]. Future Outlook - Upcoming Q3 earnings are expected to be strong catalysts for the stock, with potential for a double-digit price movement if results exceed expectations [4]. - A price target of $300 is suggested as sentiment normalizes and fundamentals reassert themselves, reinforcing the bullish outlook on PEN [4]. Historical Context - The stock price has appreciated approximately 51.23% since a previous bullish thesis was published, indicating strong market confidence in the company's innovation and growth potential [5].